ASCO 2025 | Translating splicing-derived neoantigens into clinical therapeutics
Darwin Kwok, PhD, University of California, San Francisco, CA, comments on the potential of splicing-derived neoantigens in clinical therapeutics, suggesting that these antigens could be translated into TCR transduced T cell therapies or vaccines for neoantigens discovered in the future, with the goal of in-vivo testing in a preclinical model before clinical application. This approach aims to leverage the immune system’s ability to recognize and target cancer cells. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We think that currently right now we have the TCRs, we have the transduced CD8 positive T cells that can target these neoantigens. What we’re thinking about right now is to translate them into an in-vivo study, a preclinical model, before bringing them into the clinic as a form of, let’s say, TCR transduced T cell therapies or even vaccines for neoantigens that we discovered down the line...
We think that currently right now we have the TCRs, we have the transduced CD8 positive T cells that can target these neoantigens. What we’re thinking about right now is to translate them into an in-vivo study, a preclinical model, before bringing them into the clinic as a form of, let’s say, TCR transduced T cell therapies or even vaccines for neoantigens that we discovered down the line. Thank you.
Read more...
